The focus of PARP inhibitors (PARPis) to date has been on BRCA1 and BRCA2 mutated tumours, with clinical benefits seen in patients with mutations in these DNA repair genes such as ovarian [4], breast [5], prostate [6] and pancreatic cancers [7]. The gene discussed is BRCA1; the disease is neoplasm.